Advanced diagnostics in oncology - a test bed for risk prediction in prostate cancer
|Coordinator||Lunds universitet - Medicon Village|
|Funding from Vinnova||SEK 460 000|
|Project duration||June 2015 - January 2016|
|Venture||Challenge-Driven Innovation – Stage 1 initiation|
|Call||Challenge-Driven Innovation - Stage 1 Initiation 2015 (spring)|
Purpose and goal
Here, we present a novel diagnostic assay based on our biomarker platform for implementation for prostate cancer prediction. During this project, the consortium has been strengthened as we have identified and engaged all crucial partners required for a successful implementation. We have managed to secure valuable patient samples for three retrospective studies and conducted bench marking for prostate cancer diagnostics that highlights the great need and commercial potential.
Results and expected effects
In a recent study, we demonstrate the concept of biomarker signatures in risk classifying prostate cancer patients, which reduce the risk of the proposed project. By planning three retrospective studies we have ensured clinical validation of the test. The result of this UDI step 1 project is a dedicated consortium with strengthened relations. Consequently, the specific requirements of the various partners, including the end users, have been further elucidated and defined.
Approach and implementation
Through regular meetings and workshops with the different stakeholders, both separately and in different constellations, the clinical needs have been identified and the UDI step 2 designed. Together we have outlined five work packages that will be launched upon grant approval. Internally within each party, responsibilities and action plan for this project have been discussed. Prof. Borrebaeck has been responsible for project management and the research coordinator for the implementation and daily contacts.